
OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain)[1]. OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner[2]. OSU-T315 causes cell death through apoptosis and autophagy[1].

V roku 2007 získali Nobelovu cenu za fyziológiu alebo medicínu Mario R. Capecchi (USA), Sir Martin E...
Čítať viac
Trh s farmaceutickymi a biologickymi liekmi ponuka siroku skalu pripravkov urcenych na liecbu mnohyc...
Čítať viac
S oteplovanim pocasia rastie aj riziko prisatia kliestov. Tieto drobne pavukovce prenasaju mnoho roz...
Čítať viac